EGFR-mutated lung cancer: a paradigm of molecular oncology

The development of EGFR tyrosine kinase inhibitors for clinical use in non-small cell lung cancer and the subsequent discovery of activating EGFR mutations have led to an explosion of knowledge in the fields of EGFR biology, targeted therapeutics and lung cancer research. EGFR-mutated adenocarcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhenfeng, Stiegler, Amy L., Boggon, Titus J., Kobayashi, Susumu, Halmos, Balazs
Formato: Texto
Lenguaje:English
Publicado: Impact Journals LLC 2010
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001953/
https://www.ncbi.nlm.nih.gov/pubmed/21165163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001953/
https://www.ncbi.nlm.nih.gov/pubmed/21165163

Ejemplares similares